BACKGROUND: Rosamultin (RS), a triterpenoid compound, is the main active component of the traditional Dong ethnic medicine "Madeng'ai". It has been proven to have a significant therapeutic effect on improving renal fibrosis. However, the potential role of RS in the treatment of acute kidney injury (AKI) and the underlying molecular mechanisms remain unclear. Therefore, this study investigates whether RS confers renal protection in AKI and seeks to elucidate its underlying mechanisms. METHODS: The potential mechanism of RS in alleviating AKI was preliminarily predicted through network pharmacology. Lipopolysaccharide (LPS) was used as an inducer to establish AKI models both in vivo and in vitro. The protective effect of RS on AKI was demonstrated through the detection of inflammatory factors, oxidative factors, histological examination, and renal function assessment. Quantitative real-time PCR and Western blotting were employed to investigate the Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling pathway and autophagic flux. Furthermore, non-targeted metabolomics was conducted to identify differential metabolites between the AKI model and the RS treatment group. RESULTS: RS mitigated LPS-induced inflammatory injury and promoted autophagy, resulting in reduced renal injury in BALB/c mice. In RAW264.7 cells, RS increased the formation of autophagosome and the accumulation of autophagic substrates, while reversing LPS-induced oxidative stress and inflammatory responses. Mechanistically, RS exerts its renoprotective effects through concurrent suppression of the TLR4/NF-κB signaling cascade and induction of autophagic flux. CONCLUSION: The protective effect of RS against LPS-induced renal injury is achieved by inducing autophagy and inhibiting inflammatory responses, oxidative stress and the NF-κB signaling pathway.
Rosamultin Alleviates LPS-Induced Acute Kidney Injury by Promoting Autophagy and Inhibiting the NF-κB Signaling Pathway.
阅读:1
作者:Huang Xi, Zhang Zaiqi, Cai Wei
| 期刊: | Drug Design Development and Therapy | 影响因子: | 5.100 |
| 时间: | 2026 | 起止号: | 2026 Jan 21; 20:574424 |
| doi: | 10.2147/DDDT.S574424 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
